In primary melanomas, positive COX2 immunoreactivity was significantly related to advanced Clark levels (P = .004), but no other clinicopathologic variables such as tumor growth pattern, p53 immunoreactivity, and Ki-67 labeling index. This evidence concerns the gene PTGS2 and neoplasm.